Trial Profile
A randomized, single-blind, dose-rising, placebo-controlled, crossover study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of exenatide in adolescent subjects with type 2 diabetes mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Amylin Pharmaceuticals
- 30 Oct 2007 Status changed from recruiting to completed
- 28 Oct 2006 New trial record.